Pimicotinib
Small moleculeexperimental
Clinical trial activity
12 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Dec 20, 2019 (NCT04192344)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(NC(=O)N2CCC(C)(C)C2=O)ccc1Oc1ccnc(-c2cnn(C)c2)c1- Mol. weight
- 420.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314535 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07210996 | Phase 1 | Sep 12, 2025 | Abbisko Therapeutics Co, Ltd, Jinlin University |
| NCT07126249 | Phase 1 | May 13, 2025 | Abbisko Therapeutics Co, Ltd, Jinlin University |
| NCT06884072 | Phase 1 | Apr 8, 2025 | Abbisko Therapeutics Co, Ltd, Jinlin University |
| NCT06779253 | Phase 1 | Mar 20, 2025 | Abbisko Therapeutics Co, Ltd |
| NCT06694948 | Phase 1 | Dec 28, 2024 | Abbisko Therapeutics Co, Ltd, Jinlin University |
| NCT06322706 | Phase 1 | Mar 28, 2024 | Abbisko Therapeutics Co, Ltd |
| NCT06186583 | Phase 1 | Dec 13, 2023 | Abbisko Therapeutics Co, Ltd, Soochow University |
| NCT06111274 | Phase 2 | Oct 17, 2023 | Abbisko Therapeutics Co, Ltd |
| NCT06186804 | Phase 2 | May 30, 2023 | Abbisko Therapeutics Co, Ltd |
| NCT05804045 | Phase 3 | Apr 27, 2023 | Abbisko Therapeutics Co, Ltd |
| NCT05280483 | Phase 1 | Mar 19, 2022 | Abbisko Therapeutics Co, Ltd |
| NCT04192344 | Phase 1 | Dec 20, 2019 | Abbisko Therapeutics Co, Ltd |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbisko Therapeutics Co, Ltd | For profit | 12 | 12 | 3 | 2019 |
| Jinlin University | Academic/Hospital | 4 | 0 | 1 | 2024 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1